Please Wait
Applying Filters...
Menu
$ API Ref.Price (USD/KG) : 10,449Xls
2D Structure
Also known as: 9007-72-1, Ex-a3450, (2s,3s,4s,5r)-4-[(2r,3r,4r,5s,6r)-5-[(2r,3r,4r,5s,6r)-3,4-dihydroxy-6-(hydroxymethyl)-5-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2,3,5,6-tetrahydroxyhexanoate;iron(3+);oxygen(2-);hydroxide;hydrate
Molecular Formula
C24H44FeO25-
Molecular Weight
788.4  g/mol
InChI Key
MFBBZTDYOYZJGB-HAONTEFVSA-L

Ferric Carboxymaltose is an iron replacement product and chemically, an iron carbohydrate complex. FDA approved on July 25, 2013.
1 2D Structure

2D Structure

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
(2S,3S,4S,5R)-4-[(2R,3R,4R,5S,6R)-5-[(2R,3R,4R,5S,6R)-3,4-dihydroxy-6-(hydroxymethyl)-5-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2,3,5,6-tetrahydroxyhexanoate;iron(3+);oxygen(2-);hydroxide;hydrate
2.1.2 InChI
InChI=1S/C24H42O22.Fe.2H2O.O/c25-1-5(29)18(11(32)14(35)21(39)40)44-23-16(37)12(33)20(7(3-27)42-23)46-24-17(38)13(34)19(8(4-28)43-24)45-22-15(36)10(31)9(30)6(2-26)41-22;;;;/h5-20,22-38H,1-4H2,(H,39,40);;2*1H2;/q;+3;;;-2/p-2/t5-,6-,7-,8-,9-,10+,11+,12-,13-,14+,15-,16-,17-,18+,19-,20-,22-,23-,24-;;;;/m1..../s1
2.1.3 InChI Key
MFBBZTDYOYZJGB-HAONTEFVSA-L
2.1.4 Canonical SMILES
C(C1C(C(C(C(O1)OC2C(OC(C(C2O)O)OC3C(OC(C(C3O)O)OC(C(CO)O)C(C(C(=O)[O-])O)O)CO)CO)O)O)O)O.O.[OH-].[O-2].[Fe+3]
2.1.5 Isomeric SMILES
C([C@@H]1[C@H]([C@@H]([C@H]([C@H](O1)O[C@@H]2[C@H](O[C@@H]([C@@H]([C@H]2O)O)O[C@@H]3[C@H](O[C@@H]([C@@H]([C@H]3O)O)O[C@@H]([C@@H](CO)O)[C@H]([C@@H](C(=O)[O-])O)O)CO)CO)O)O)O)O.O.[OH-].[O-2].[Fe+3]
2.2 Synonyms
2.2.1 MeSH Synonyms

1. Ferinject

2. Injectafer

3. Iron Carboxymaltose

4. Iron Dextri-maltose

5. Polynuclear Iron (iii)-hydroxide 4(r)-(poly-(1->4)-o-alpha-d-glucopyranosyl)-oxy-2(r),3(s),5(r), 6-tetrahydroxy-hexanoate

6. Vit 45

7. Vit-45

2.2.2 Depositor-Supplied Synonyms

1. 9007-72-1

2. Ex-a3450

3. (2s,3s,4s,5r)-4-[(2r,3r,4r,5s,6r)-5-[(2r,3r,4r,5s,6r)-3,4-dihydroxy-6-(hydroxymethyl)-5-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2,3,5,6-tetrahydroxyhexanoate;iron(3+);oxygen(2-);hydroxide;hydrate

2.3 Create Date
2014-11-22
3 Chemical and Physical Properties
Molecular Weight 788.4 g/mol
Molecular Formula C24H44FeO25-
Hydrogen Bond Donor Count16
Hydrogen Bond Acceptor Count25
Rotatable Bond Count13
Exact Mass788.152102 g/mol
Monoisotopic Mass788.152102 g/mol
Topological Polar Surface Area382 Ų
Heavy Atom Count50
Formal Charge-1
Complexity940
Isotope Atom Count0
Defined Atom Stereocenter Count19
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count5
4 Drug and Medication Information
4.1 Drug Information
1 of 2  
Drug NameInjectafer
PubMed Healthferric carboxymaltose
Drug ClassesIron Supplement
Drug LabelFerric carboxymaltose, an iron replacement product, is an iron carbohydrate complex with the chemical name of polynuclear iron (III) hydroxide 4(R)-(poly-(14)-O--D-glucopyranosyl)-oxy-2(R),3(S),5(R),6-tetrahydroxy-hexanoate. It has a relative mo...
Active IngredientFerric carboxymaltose
Dosage FormInjectable
RouteIntravenous
Strength750mg iron/15ml (50mg iron/ml)
Market StatusPrescription
CompanyLuitpold
Patent7612109; 7754702

2 of 2  
Drug NameInjectafer
PubMed Healthferric carboxymaltose
Drug ClassesIron Supplement
Drug LabelFerric carboxymaltose, an iron replacement product, is an iron carbohydrate complex with the chemical name of polynuclear iron (III) hydroxide 4(R)-(poly-(14)-O--D-glucopyranosyl)-oxy-2(R),3(S),5(R),6-tetrahydroxy-hexanoate. It has a relative mo...
Active IngredientFerric carboxymaltose
Dosage FormInjectable
RouteIntravenous
Strength750mg iron/15ml (50mg iron/ml)
Market StatusPrescription
CompanyLuitpold
Patent7612109; 7754702

4.2 Drug Indication

Ferric carboxymaltose is a iron replacement product indicated for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron or those who have non-dialysis dependent chronic kidney disease.


FDA Label


5 Pharmacology and Biochemistry
5.1 Pharmacology

When measured using positron emission tomography (PET), the red cell uptake of 59-Fe and 52-Fe from INJECTAFER ranged from 61% to 99%. In patients with iron deficiency, the red cell uptake ranged from 91% to 99%. In patients with renal anemia, the red cell uptake ranged from 61% to 84%.


5.2 FDA Pharmacological Classification
5.2.1 Pharmacological Classes
Parenteral Iron Replacement [EPC]; Phosphate Binder [EPC]; Phosphate Chelating Activity [MoA]; Iron [CS]
5.3 Absorption, Distribution and Excretion

Absorption

When a single dose of 100 to 1000 mg of iron was given to iron deficient patients, the maximum serum concentration (Cmax) was 37 g/mL to 333 g/mL. These levels were obtained 15 minutes to 1.21 hours post dose (Tmax).


Route of Elimination

Renal elimination of iron was negligible.


Volume of Distribution

3 L


5.4 Biological Half-Life

7 to 12 hours.


5.5 Mechanism of Action

Ferric carboxymaltose is a colloidal iron (III) hydroxide in complex with carboxymaltose, a carbohydrate polymer that release iron.